Schonfeld Strategic Advisors LLC Has $29.88 Million Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Schonfeld Strategic Advisors LLC lifted its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 355.7% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 127,000 shares of the biopharmaceutical company's stock after purchasing an additional 99,133 shares during the quarter. Schonfeld Strategic Advisors LLC owned about 0.10% of Alnylam Pharmaceuticals worth $29,884,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of ALNY. Larson Financial Group LLC increased its position in shares of Alnylam Pharmaceuticals by 187.2% during the fourth quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company's stock worth $26,000 after acquiring an additional 73 shares in the last quarter. R Squared Ltd bought a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter valued at about $33,000. OFI Invest Asset Management acquired a new position in shares of Alnylam Pharmaceuticals during the fourth quarter worth about $35,000. Versant Capital Management Inc grew its holdings in shares of Alnylam Pharmaceuticals by 77.6% during the fourth quarter. Versant Capital Management Inc now owns 190 shares of the biopharmaceutical company's stock worth $45,000 after buying an additional 83 shares in the last quarter. Finally, IFP Advisors Inc raised its position in Alnylam Pharmaceuticals by 24.2% in the 4th quarter. IFP Advisors Inc now owns 241 shares of the biopharmaceutical company's stock valued at $57,000 after buying an additional 47 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Stock Performance

NASDAQ:ALNY traded up $4.26 during mid-day trading on Friday, reaching $259.39. 729,702 shares of the company's stock were exchanged, compared to its average volume of 885,109. Alnylam Pharmaceuticals, Inc. has a one year low of $144.73 and a one year high of $304.39. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78. The business's fifty day simple moving average is $248.21 and its two-hundred day simple moving average is $255.31. The firm has a market capitalization of $33.74 billion, a PE ratio of -119.53 and a beta of 0.30.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.07). The firm had revenue of $594.19 million for the quarter, compared to the consensus estimate of $584.32 million. During the same period last year, the firm posted ($0.16) EPS. The company's quarterly revenue was up 20.2% compared to the same quarter last year. Analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, CMO Pushkal Garg sold 1,548 shares of the business's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $251.67, for a total transaction of $389,585.16. Following the completion of the transaction, the chief marketing officer now directly owns 11,989 shares in the company, valued at $3,017,271.63. The trade was a 11.44 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Jeffrey V. Poulton sold 967 shares of the company's stock in a transaction on Friday, February 14th. The stock was sold at an average price of $255.17, for a total value of $246,749.39. Following the sale, the chief financial officer now owns 32,786 shares of the company's stock, valued at $8,366,003.62. The trade was a 2.86 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 7,392 shares of company stock worth $1,875,627. Company insiders own 1.50% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on ALNY shares. Needham & Company LLC reaffirmed a "buy" rating and set a $320.00 price target on shares of Alnylam Pharmaceuticals in a research note on Wednesday, April 9th. Wells Fargo & Company boosted their price target on shares of Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the stock an "equal weight" rating in a research report on Friday, March 21st. StockNews.com cut Alnylam Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Wednesday. Bank of America upped their target price on Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the stock a "buy" rating in a report on Friday, March 21st. Finally, Canaccord Genuity Group boosted their price target on Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the stock a "buy" rating in a research report on Friday, March 21st. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and twenty-one have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $319.17.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.